First-line drug in the treatment of hormone-dependent metastatic breast cancer in postmenopause

8 February

We are pleased to inform you that we obtained the marketing authorizations for the antitumor hormonal agent Toremifen VIVA Pharm, tables in doses of 20 mg (РК-ЛС-5№023518) and 60 mg (РК-ЛС-5№023519).

Toremifen Viva Pharm is indicated for the treatment of hormone-dependent metastatic breast cancer in postmenopause as a first-line drug, as well as for the prevention and treatment of dishormonal breast hyperplasia.

Back to the news
Thank you
Ваш вопрос отправлен. Ответ на него будут опубликованы после проверки администратором
Close
Website:
Закрыть